Valiant Laboratories

VALIANTLAB · NSE

— · —

₹104.89

Closing price — 27 Aug 2026

Market cap ₹603 Cr · EPS ₹2.30

Valuation

Blended fair value using DCF and peer comparison methods.

See if Valiant Laboratories is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Healthcare · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Valiant Laboratories VALIANTLAB · you	₹603 Cr	45.7×	2.6×	—	5.8%	0.1%	—
Sector median	—	35.9×	5.2×	22.6×	13.9%	1.7%	0.9%
Gujarat Themis Biosyn Limited GUJTHEM	₹4,480 Cr	81.1×	13.2×	61.4×	16.2%	28.2%	3.6%
Aarti Drugs Limited AARTIDRUGS	₹3,901 Cr	20.0×	2.5×	13.4×	12.6%	7.6%	-1.9%
Unichem Laboratories Limited UNICHEMLAB	₹3,793 Cr	22.8×	1.6×	—	7.0%	0.0%	—
Novartis India Limited NOVARTIND	₹3,671 Cr	41.0×	4.7×	31.9×	11.4%	26.3%	-2.2%
Kwality Pharmaceuticals Limited KPL	₹3,574 Cr	44.1×	14.7×	—	33.4%	0.2%	—
SMS Pharmaceuticals Limited SMSPHARMA	₹3,377 Cr	37.3×	5.7×	—	15.2%	0.1%	—
Dishman Carbogen Amcis Limited DCAL	₹2,821 Cr	31.9×	0.5×	5.9×	1.5%	3.3%	6.7%
Vimta Labs Limited VIMTALABS	₹2,754 Cr	34.6×	8.1×	—	23.6%	0.2%	—

Peer comparison verdict

Valiant trades at a premium to sector peers on P/E (45.7× vs median 35.9×). The market is pricing in higher growth — worth verifying whether recent revenue trends support that expectation.

Business quality

Valuation

P/E ratio

45.7×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

5.8%

ROCE

—

ROA

—

Growth

Revenue CAGR (3yr)

—

EPS CAGR (3yr)

—

Efficiency

Asset turnover

—

FCF yield

—

Dividend yield

—

Liquidity & Solvency

Debt / Equity

—

Debt / EBITDA

—

Interest coverage

—

Current ratio

—

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Income statement data is unavailable for this company.

Cash flow

Where cash comes from and where it goes.

Cash flow data is not yet available for this company.

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

Balance sheet data is not yet available for this company.

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

Shareholding data is not yet available for this company.